INDIVIDUAL ARTICLE: New Horizons in Our Understanding of Prurigo Nodularis and Its Management

Overview of attention for article published in Journal of Drugs in Dermatology, November 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#39 of 1,776)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news: 13 news outlets

So far, Altmetric has seen 20 news stories from 13 outlets.

Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis

AFP, 11 Mar 2024

Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other…

Press Release from Business Wire: Galderma

UrduPoint, 10 Mar 2024

ZUG, (APP - UrduPoint / Pakistan Point News - 11th Mar, 2024) Galderma today announced new data demonstrating nemolizumab's long…

News story from Finanz Nachrichten on Sunday 10 March 2024

Finanz Nachrichten, 10 Mar 2024

Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis

ADFN, 10 Mar 2024

Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31 One-y…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 16 additional news stories.